Scalper1 News
Enthusiasm about potential cancer cures sent shares of Juno Therapeutics (JUNO) and its peers flying Thursday, though Juno’s fourth-quarter earnings late Wednesday missed Wall Street estimates by a lot. “Within the next 12 months, we expect to have 10 product candidates in clinical development directed at six different cancer-associated antigens,” Juno CEO Hans Bishop said in the company’s earnings press release. Juno stock was up 15% in afternoon Scalper1 News
Scalper1 News